Inhibition of IL-6 and IL-8 production in human fibroblast cell lines by 1,25 (OH)2 vitamin D3 and two of its analogs with lower calcemic activity.
In human fibroblast cultures TPA increased IL-6 and IL-8 production. This was reduced by vitamin D3 metabolites and analogs. The two analogs employed: 1,25 (OH)2-22 (E)-dehydro-24-monohomo vitamin D3 (Compound A) and 1,25 (OH)2 -22 (E)-dehydro-24 dihomo-vitamin D3 (Compound B) may be useful in the therapy of pathologic proliferative disorders including psoriasis, particularly since they are less toxic and have less effect on calcium metabolism than vitamin D3.
Srviastava
M D
MD
State University of New York at Buffalo.
DeLuca
H
H
Ambrus
J L
JL
D002117:Calcitriol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D016209:Interleukin-8 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011565:Psoriasis / Q000188:drug therapy; D012867:Skin; D000093242:Interleukin-6 Inhibitors
D002117:Calcitriol; D002118:Calcium; D015850:Interleukin-6; D016209:Interleukin-8; D000093242:Interleukin-6 Inhibitors; C087590:22-dehydro-1,25-dihydroxy-24-homovitamin D3; C087591:22-dehydro-1,25-dihydroxy-24-dihomovitamin D3